1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
enGene Holdings Inc. Warrants

enGene Holdings Inc. Warrants

ENGNW
enGene Holdings Inc. WarrantsUS flagNASDAQ Capital Market
0.28
USD
-0.06
- -
14.34MMarket Cap
enGene Holdings Inc. Warrants
ENGNW
(NASDAQ Capital Market)

Recent

price

0.28

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
Depreciation Expense
-15
-23
-24
-100
-55
-117
-127
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
10
17
80
233
169
249
Working Capital
- -
3
31
9
24
22
31
LT Debt
- -
- -
-23
72
273
168
255
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-35.03
-59.19
-62.65
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Oct'25
Jan'26
Apr'26
ST Debt
10
3
2
LT Borrowings
15
25
25
LT Finance Leases
6
6
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
52
67
67
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Oct'25
Jan'26
Apr'26
Total Current Assets
201
289
270
Cash, Cash Equivalents & STI
194
276
258
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
32
25
21
Payables & Accruals
17
16
16
ST Debt
10
3
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-38.48%
Free Cash Flow
- -
54.81%
104.7%
Net Income, GAAP
- -
87.26%
112.73%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Calliditas Therapeutics AB (publ) (CALTX.ST)
Asarina Pharma AB (publ) (ASRPF)
Shanghai Model Organisms Center, Inc. (688265.SS)
ZIVO Bioscience, Inc. (ZIVOW)
Pharmiva AB (publ) (PHARM.ST)
NeuroBo Pharmaceuticals, Inc. (NRBO)
Business
enGene Holdings Inc. is a clinical-stage biotechnology company that develops non-viral genetic medicines for delivery to mucosal tissues and other organs, with a primary focus on urological cancers including non-muscle invasive bladder cancer (NMIBC). The company offers detalimogene voraplasmid (previously EG-70), a non-viral gene therapy monotherapy evaluated in the ongoing pivotal LEGEND Phase 2 trial for high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS); and the proprietary DDX (dually derivatized oligochitosan) gene delivery platform, which enables localized, re-dosable delivery of gene cargos such as DNA and RNA to mucosal tissues in the bladder, lung, gastrointestinal tract, and urinary tract. Founded in 1999 and headquartered in Montreal, Quebec, Canada, with U.S. operations in Boston, Massachusetts, enGene Holdings operates through its subsidiary enGene, Inc. and targets patients with high unmet needs in oncology, particularly those unresponsive to standard BCG therapy. Recent developments include a $60 million private placement financing in October 2024 with investors such as Deep Track Capital, Cormorant Asset Management, Forbion, OrbiMed, Sphera Healthcare, Vestal Point Capital, and Venrock Healthcare Capital Partners to support detalimogene development, pre-commercial activities, DDX platform expansion, and operations into 2027; a prior oversubscribed $200 million private placement in February 2024; and the adoption of the 2025 Employee Stock Purchase Plan in June 2025 along with inducement stock option awards.